|
Unipolar Depression
|
0.310 |
Biomarker
|
disease |
BEFREE |
Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression.
|
16710089 |
2006 |
|
Unipolar Depression
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression.
|
16710089 |
2006 |
|
Major Depressive Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression.
|
16710089 |
2006 |
|
Major Depressive Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression.
|
16710089 |
2006 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
These results suggested that LBP1C-2 might be a leading compound for anti-Alzheimer's disease therapy by decreasing Aβ<sub>42</sub> production through mediating BACE1 and ADAM10 as well as IDE expression.
|
30241864 |
2018 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
The virus binds to the host transcription factors transcription factor CP2 (TFCP2) and POU2F1 that control many other genes associated with Alzheimer's disease.
|
18164103 |
2008 |
|
Alzheimer's Disease
|
0.080 |
AlteredExpression
|
disease |
LHGDN |
(4) The virtual screen identified CP2/LBP-1c/LSF as a factor that likely mediates enhanced transcription of GARS-AIRS-GART in DS-related AD.
|
17902044 |
2007 |
|
Alzheimer's Disease
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
(4) The virtual screen identified CP2/LBP-1c/LSF as a factor that likely mediates enhanced transcription of GARS-AIRS-GART in DS-related AD.
|
17902044 |
2007 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Association of polymorphism in the transcription factor LBP-1c/CP2/LSF gene with Alzheimer's disease and major depression.
|
16710089 |
2006 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
LHGDN |
This is the first study to examine LBP-1c/CP2/LSF in AD families, and the fifth to independently show significant association.
|
16272261 |
2005 |
|
Alzheimer's Disease
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that the LBP-1c/CP2/LSF polymorphism may have a moderate protective effect against the risk of AD.
|
12555245 |
2003 |
|
Alzheimer's Disease
|
0.080 |
GeneticVariation
|
disease |
LHGDN |
Our data suggest that the LBP-1c/CP2/LSF polymorphism may have a moderate protective effect against the risk of AD.
|
12555245 |
2003 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Our data support LBP-1c/CP2/LSF as a candidate gene/risk factor for AD and provide justification for future studies to investigate the role of this gene in Alzheimer's disease.
|
11283204 |
2001 |
|
Alzheimer's Disease
|
0.080 |
Biomarker
|
disease |
BEFREE |
Our data suggest that polymorphic variation in the implication of the LBP-1c/CP2/LSF gene may be important for the pathogenesis of AD, particularly since LBP-1c/CP2/LSF interacts with proteins such as GSKbeta, Fe65 and certain factors involved in the inflammatory response.
|
11001930 |
2000 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
To evaluate the feasibility of a same-day yttrium-90 (<sup>90</sup>Y) radioembolization protocol with resin microspheres (including pretreatment angiography, lung shunt fraction [LSF] determination, and radioembolization) for the treatment of hepatocellular carcinoma (HCC) and liver metastases.
|
30819470 |
2019 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer.
|
29410248 |
2018 |
|
Liver carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Of the 7 SNPs in TFCP2, rs7959378 distributed differentially between patients with versus patients without HCC.
|
28348581 |
2017 |
|
Liver carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The transcription factor LSF is highly expressed in hepatocellular carcinoma (HCC) and promotes oncogenesis.
|
27845898 |
2016 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma.
|
26378040 |
2015 |
|
Liver carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis.
|
25609232 |
2015 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Clinically, CCT3 was positively correlated with YAP and TFCP2, and elevated levels of the CCT3-YAP-TFCP2 axis might be critical for liver malignancy.
|
31501420 |
2019 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
The results showed MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) expression were associated with some clinical features in patients, such as pathological differentiation, tumor size, clinical stage, lymph node metastasis and distant metastasis.
|
31126819 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer.
|
31501420 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Clinically, CCT3 was positively correlated with YAP and TFCP2, and elevated levels of the CCT3-YAP-TFCP2 axis might be critical for liver malignancy.
|
31501420 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
For example, there are numerous parallels between placental development and cancer growth; therefore, investigating the roles of TFCP2, TFCP2L1, and UBP1 in the placenta may help us better understand their functioning in cancer, as is evidenced by the studies of various other proteins and pathways.
|
30241344 |
2018 |